(MedPage Today) — BERLIN — Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression with the addition of radioligand therapy to hormonal treatment, a large randomized trial showed…

Read the full article on medpagetoday.com